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Objective/Background: Tuberculosis (TB) is a re-emerging disease with the advent of human
immunodeficiency virus/AIDS infections. Discovered in 1959, diagnosed by various
approaches and treated with antibiotics, the treatment of TB infection still poses public
health concerns. Many cases of resistance and cross-resistance are observed. Diagnosis
by culture, which is considered as the standard method, takes too long (20–30 days) and
is not suitable for extrapulmonary TB. QuantiFERON test, which is an indirect immunoas-
say based on blood, was developed. Much hope was placed in this new approach because it
is based on blood, and many research teams have used it. We discuss the results of these
different research groups who have used QuantiFERON for diagnosis, prediction of disease
progression, or monitoring patients during the treatment of TB.
Methods: Articles published in PubMed and documents published on Google were searched
with the keywords: diagnosis and TB and QuantiFERON; TB and QuantiFERON and thera-
peutic monitoring; interferon-c release assay; disease progression. These articles were read
and analyzed.
Results: The results were controversial with regards to using the QuantiFERON test for the
diagnosis of TB according to the study population (ethnic group, bacillus Calmette–Gue´rin
vaccine use) and according to the state of the immune system of the people studied
(human immunodeficiency virus immunosuppression in cancer medication, hyperten-
sion). Also, research findings were controversial with regards to using QuantiFERON for
monitoring TB patients on anti-TB medications. Also, the predictive positive value for the
progression to TB among immigrant close contacts of both interferon-c release assays
was not better than that of the tuberculin skin test.ement, PO
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population studied. Recommendations are made to improve the sensitivity and specificity
and to differentiate between latent and active TB by adding other specific proteins in the
Mycobacterium tuberculosis antigen cocktail.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Roughly one-third of the world’s population is infected with
Mycobacterium tuberculosis (Mtb), and new infections occur at
a rate of one per second on a global scale [1]. Insufficient
access to advanced diagnostic tests has contributed to subop-
timum performance in the detection of tuberculosis (TB). To
date, national TB programs in disease endemic countries con-
tinue to rely largely on antiquated and not very accurate
methods such as direct smear microscopy, solid culture, and
chest radiography [2]. Most, if not all, of these techniques
have their drawbacks. Direct microscopic examination of spu-
tum samples and culture of mycobacteria (presently the gold
standards for the diagnosis of TB) sometimes give false nega-
tive results due to poor sample collection or paucibacillary. In
some cases, patients such as infants younger than 6 years
lack the required expectorates and are unable to produce spu-
tum for analysis. Diagnosis of smear-negative TB still poses
substantial clinical challenges including diagnosis of extra-
pulmonary TB. Childhood TB is a well-known diagnostic chal-
lenge, and all available tests do poorly in cases of
paucibacillary TB [3]. The absence of a gold standard for extra-
pulmonary TB and smear-negative TB is an important imped-
iment to rapid assessment of new diagnostic methods in
these subgroups. Diagnostic delays and misdiagnosis results
in increased morbidity and mortality in patients, and allow
continued transmission of TB [4].
One blood-based test which has existed since 1910 is the
tuberculin skin test (TST). Its principle relies on in vivo detec-
tion of delayed-type hypersensitivity to purified protein
derivatives, a mixture of antigens shared by many mycobac-
teria that gives rise to a skin reaction [5]. The main drawback
of the TST is its poor specificity as previous bacillus Calmette–
Gue´rin (BCG) vaccination and non-TB mycobacterial exposure
can lead to false-positive results.
The other blood-based test available is the QuantiFERON
test (QFT). The QFT is a type of enzyme-linked immunoassay
(ELISA) used for the diagnosis of TB. There are two commer-
cial QFTs available and approved by the United States Food
and Drug Administration (FDA): the enzyme-linked
immunospot-based assay T-SPOT.TB (Oxford Immunotech,
Oxford, UK) and the whole blood ELISA-based format
QuantiFERON-TB Gold In-Tube (QFT-GIT), provided by Celles-
tis (Carniege, Victoria, Australia). Memory Mtb T-cell specific
antigens are used in both tests. These tests have early secre-
tory antigen target 6 (ESAT-6) and culture filtrate protein 10
(CFP-10) antigens in common, with QFT-GIT having TB7.7
antigen in addition. ESAT-6, CFP-10 (encoded by genomic
region of difference 1), and TB7.7 (encoded by region ofdifference 11) are selectively restricted to Mtb while it is
absent in most environmental mycobacteria and in all BCG
vaccine strains [6,7]. The QFT-GIT is sometimes abbreviated
to QFT-3G. The predecessor, abbreviated as QFT-2G, made
use of just two antigens; CFP-10 and ESAT-6. The QFT-GIT
offers a number of advantages compared with the TST,
including increased specificity in persons who have had a
BCG vaccination, and elimination of the need for a second
visit to read the TST. The QFT-GIT is used to detect both latent
and active TB but cannot distinguish between both.
With the QFT-GIT based on blood and its ability to detect
both latent and active TB, it should be a preferable test with
respect to the drawbacks associated with TST. There have
been a lot of controversies on the use of the QFT test in diag-
nosing TB in immunocompromised individuals and in moni-
toring treatment with anti-TB agents. In this systematic
review, we look at the advantages and the limits of the QFT-
GIT (the most recent version of the QFT test) in the diagnosis
of TB and in treatment follow-up in adults. This will be of help
to policy makers on strategy implementation in Mtb diagnosis
and treatment follow-up, as well as researchers in orienting
focus on how to upgrade the QFT-GIT to make it a better diag-
nostic test.
Materials and methods
We searched PubMed online, which is a free search engine
accessing primarily the Medline database of references and
abstracts on life sciences and biomedical topics. We searched
for articles related to the topics: ‘‘QuantiFERON test in tuber-
culosis’’ and ‘‘QuantiFERON test in tuberculosis diagnosis and
treatment follow-up,” ‘‘IGRA and prediction of disease pro-
gression.” From all the articles we were able to download,
we searched their references, selected, and also downloaded
related articles and reviews including the updated guidelines
for using interferon-c released assays (IGRAs) to detect Mtb
infection by Centers for Disease Control in 2010 [8]. Some
related articles were obtained from the Cellestis package
insert on QFT TB gold (in-tube method) [9].
Results and discussion
Our search on the topic: ‘‘QuantiFERON test in tuberculosis”
gave us a total of 883 papers. When we screened this number
by searching for papers directly related to our topic of review
(‘‘QuantiFERON test in tuberculosis diagnosis and treatment
follow-up”), the search gave a total of 54 papers which we
exploited together with related references to write this
review.
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QFT is the registered trademark of the test for TB infection or
latent TB. QFT is an IGRA used in TB diagnosis. QFT-GIT, the
third generation test, has replaced QFT and QFT-Gold (QFT-
G), which are no longer marketed. The QFT-TB test is the first
generation QFT test that was first approved by the US FDA in
2001 [10] as an aid for detecting latent Mtb infection. This test
is an in vitro diagnostic aid that measures a component of
cell-mediated immune reactivity to Mtb. The test is based
on the quantification of interferon-gamma (IFN-c) released
from sensitized lymphocytes in whole blood incubated over-
night with purified protein derivative from Mtb and control
antigens. The QFT-G is the second generation QFT test. Some
authors have abbreviated it as QFT-2G to indicate it is the sec-
ond generation QFT test. This test was approved by the US
FDA in 2005. For QFT-G, the antigens include mixtures of syn-
thetic peptides representing two Mtb proteins: ESAT-6 and
CFP-10. The QFT-GIT is the third most recent version of the
QFT test and was approved by the US FDA in 2007 [11]. The
QFT-GIT makes use of three antigens: CFP-10, ESAT-10, and
TB7.7 unlike its predecessor QFT-G that had just two antigens:
CFP-10 and ESAT-10. Some authors have abbreviated QFT-GIT
as QFT-3G to identify the fact that it is the third generation
QFT test. Presently, there are two commercial QFT tests avail-
able and approved by the US FDA: the enzyme-linked
immunospot-based assay T-SPOT.TB and the whole bloodTable 1 – A summary of some previous work carried out by differ
monitoring.
Authors Tests used Results obtained
T0 (before
treatment)
T
of
Katiyar et al. (2008) [12] Microscopy &/or
culture
76 positives –
QFT (QFT-GIT) – 17
59
Bocchino et al. (2010) [13] Microscopy &/or
culture
60 positives –
QFT (QFT-GIT) 53 positives
7 negatives
Helmy et al. (2012) [14] Microscopy &/or
culture
29 positives 03
24
QFT (QFT-GIT) 24 positives
5 negatives
04
23
Denkinger et al. (2013) [15] Microscopy &/or
culture
149 positives 18
11
QFT (QFT-GIT) 133 positives
16 negatives
12
19
Mansour et al. (2014) [16] Microscopy &/or
culture
25 positives –
QFT (T-SPOT TB) – –
Note. IFN-c = interferon-gamma; mo = month; Mtb =Mycobacterium tuber
QuantiFERON-Gold In-tube; TB = tuberculosis; T0 = pretreatment test ca
2 months of treatment with anti-TB; T6 = results obtained after 6 monthELISA-based format QFT-GIT. The change from one QFT ver-
sion to another (QFT to QFT-G to QFT-GIT) has always been
about increasing its performance, although it still has some
limits to date.
QFT-GIT tests and treatment monitoring of TB
There have been a lot of controversies regarding the use of the
QFT-GIT tests in the treatment and follow-up of TB patients.
Some authors seem to approve of the idea that the QFT-GIT
tests could be a monitoring tool for the treatment of TB while
others are of the opposite opinion. Out of a total of 11 papers
that our search gave us on this topic, just two authors (18%)
were of the opinion that the QFT-GIT test could be a monitor-
ing tool for the treatment of TB. Table 1 summarizes some of
the previous work carried out on the use of QFT tests in treat-
ment monitoring.
In the studies carried out by Katiyar et al. [12] and Helmy
et al. [14], there were significant decreases in the proportion
of positive responders to the IFN-c tests during the treatment
compared with that at the beginning of the therapy. These
results strengthen the idea of the use of the QFT-GIT tests
for monitory treatment response. But it is difficult to draw a
conclusion on the use of QFT-GIT for treatment monitoring
of TB as some individuals cured of TB still had positive QFT-
GIT tests results. Other studies [13,15–17], however, tend to
demonstrate a significantly large number of QFT-test positiveent authors on the use of the QuantiFERON test in treatment
Author’s conclusions
2 (after 2 mo
treatment)
T6 (after 6 mo
of treatment;
end of treatment)
– The QFT-G can potentially
be used as a tool to
monitor the efficacy of
anti-TB treatment
positives
negatives
–
60 negatives QFT adds no significant
information to clinicians
for treatment monitoring
due to IFN-c persistence
even after successful cure
38 positives
22 negatives
positives
negatives
25 negatives There is a correlation
between clinical treatment
outcome & changes in IFN-
c response to Mtb
positives
negatives
04 positives
21 negatives
positives
9 negatives
– QFT results do not offer
much value for treatment
monitoring of TB disease5 positives
negatives
108 positives
26 negatives
2 positives
23 negatives
The QFT (T-SPOT) is a weak
test for use in treatment
monitory. The QFT test
should not be considered
as a surrogate marker for a
cure
21 positives
4 negatives
culosis; QFT = QuantiFERON; QFT-G = QuantiFERON-Gold; QFT-GIT =
rried out before initiation of treatment; T2 = results obtained after
s of treatment with anti-TB.
Table 2 – A summary of some previous work carried out on the QuantiFERON tests and immunocompromised persons.
Authors Population/country of
study
Description of
immunocompromised
conditions
QFT test results Authors’ conclusions Final verdict
Kobashi et al.
(2007) [24]
This study was carried
out in Kawasaki Japan
252 immunocompromised
patients suspected of TB
among whom were; 74 with
malignant diseases (CD4
count 208 ± 31), 72 with
immunosuppressive
treatment (CD4 count 114
± 29), 52 with diabetes
mellitus (CD4 count 220
± 36), 50 with chronic renal
failure (CD4 count 212 ± 32),
& 4 with HIV (CD4 count 40)
The positive rate of the QFT-
TB test for the diagnosis of
TB infection (active or latent
TB infection) was 78%. An
indeterminate result for the
QFT-TB test was recognized
in 12.7% (32 out of 252
immunocompromised
patients) & it appeared most
frequently in patients
receiving
immunosuppressive
treatments who presented
with lymphocytopenia
(especially CD4
lymphocytopenia)
The QuantiFERON TB-2G test
result showed an
indeterminate response for
patients receiving
immunosuppressive
treatment, especially with
lymphocytopenia due to
severe underlying diseases.
Therefore, care must be
taken when making a
diagnosis of tuberculosis in
immunocompromised
patients based on
QuantiFERON TB-2G test
results
The authors’ conclusion
support the opinion that,
immunosuppression affects
the performance of the
QuantiFERON test
Hornum et al.
(2008) [25]
This study was carried
out in Copenhagen
Denmark
4 active TB patients
confirmed by culture among
whom; 1 HIV positive patient
with CD4 count of 290, two
kidney-transplanted patients
on immunosuppressive
drugs (steroids,
mycophenolate mofetil, &
cyclosporin), & 1
malnourished patient who
was a smoker & had a history
of alcohol abuse
All 4 patients gave a false
negative QFT-2G test
A negative IFN-c test does
not exclude TB disease in
immunosuppressed patients
These authors are in support
of the opinion that
immunosuppressiveness
affects the performance of
the QuantiFERON test
Kobashi et al.
(2009) [26]
This study was carried
out in Kawasaki in Japan
140 patients were confirmed
with active TB. 10 of the 140
had a CD4 count of 254 ± 28.
115 of the 140 had a CD4
count of 392 ± 30
All 10 TB patients with CD4
count of 254 ± 28 showed a
false negative QFT test while
the other TB patient group of
115 with CD4 count of 392
± 30 showed a positive QFT-
2G test
False negative results in the
QFT test may originate from
a decrease in IFN-c
production due to
lymphocytopenia, advanced
age of patient, or lack of
ability to produce IFN-c
Authors are in support of the
opinion that the
performance of the
QuantiFERON test is affected
by immunosuppressiveness
1
8
0
I
n
t
e
r
n
a
t
io
n
a
l
Jo
u
r
n
a
l
o
f
M
y
c
o
b
a
c
t
e
r
io
l
o
g
y
5
(2
0
1
6
)
1
7
7
–
1
8
4
Maximilian & Rieger,
2009 [27]
This study was carried
out in Vienna Austria
830 HIV infected patients
diagnosed with the QFT-
GIT. Only 11 were
confirmed at the end of
study period to have
active TB
Out of the 830 HIV-infected
patients, 44 (4 with CD4
count < 200, 12 with CD4
count between 200 & 350, &
28 with CD4 count > 350)
showed a positive QFT test
result, 739 (107 with CD4
count < 200, 180 with CD4
count between 200 & 350, &
452 with CD4 count > 350)
showed negative QFT results
while 47 (25 with CD4
count < 200, 8 with CD4
count between 200 & 350, &
14 with CD4 count > 350)
showed indeterminate QTF
results
The QFT-GIT assay may be a
sensitive tool for the
detection & prediction of
active tuberculosis in HIV-1-
infected individuals
This conclusion does not
tally with presented results.
Authors are against the
opinion that
immunosuppressiveness
affects the performance of
the QuantiFERON test
Lange et al. (2010) [23] This study was carried
out in Freiburg Germany
Patients had either
undergone organ
transplantation or stem
cell transplantation (39%
rheumatoid arthritis, 12%
systemic lupus
erythematosus, 5%
chronic inflammatory
bowel disease, 44% other
autoimmune diseases),
had been receiving
immunosuppressive
therapy for at least 6 mo
& had primary
immunodeficiencies (82%
with chronic variable
immunodeficiency
syndrome) or HIV-
infection (mean CD4
count: 435)
The overall rate of
indeterminate result in
immunocompromised
patients was significantly
higher than in the control
group (p = .001)
Different disease groups bear
an independent risk of
indeterminate results in the
QFT-GIT. Low lymphocytes,
low CD8 T-cells, &
hemoglobin levels are better
predictors of indeterminate
QFT results than disease
group or
immunosuppressive
medication
Are for the opinion that the
performance of the
QuantiFERON test is affected
by immunosuppression
Note. CD4 values are reported as mean ± standard deviation. HIV = human immunodeficiency virus; IFN-c = interferon-gamma; mo = month; QFT = QuantiFERON; QFT-G = QuantiFERON-Gold; QFT-
GIT = QuantiFERON-Gold In-tube; TB = tuberculosis.
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who have been declared cured of TB. According to Chee
et al. [18], T-cell response to ESAT-6 may persist as a scar of
previously treated or quiescent infection, whereas that to
CFP-10 may be more indicative of active infection because
this response appears to be influenced by TB treatment (it
decreases over time upon successful treatment). With respect
to this point, the QFT-GIT, which is the latest improvement
from the previous in-plate format, is of limited usefulness
since all the antigens are tested simultaneously in a single
tube. These antigens could be re-evaluated by testing each
individually, but this would reduce the test sensitivity. This
test assesses the Mtb specific central memory T-cell
responses to selected Mtb antigens. These cells are long lived
cells, and will therefore give positive QTF-GIT test results for
already cured people. Quantifying the relative amount of
IFN-c released as treatment goes on could be a suitable
approach to increase the usefulness of the QFT-GIT in treat-
ment management.
Wu-Hsieh and collaborators [19] also showed that cured TB
patients could retain strong ESAT-6 responses for several
years after completion of treatment. Eum et al. [20], showed
that the regulation of tumor necrosis factor (TNF) during ther-
apy might be better than IFN-c in predicting sputum conver-
sion at 6 months. The QFT-GIT test therefore has a limit in
that it cannot be used to monitor treatment of TB. Modifica-
tions in the QFT tests might be of enormous importance for
treatment follow-up like re-evaluating CFP-10, looking for a
possibility of using TNF as another marker, or modifying the
cut-off levels [21].
QFT tests and immunocompromised individuals
Our search gave us a total of 12 articles on the QFT tests and
immunocompromised persons. Three authors (25%) were of
the opinion that immunosuppressiveness does not affect
the performance of the QFT tests, while the other nine
authors, 75%, were of the opposite opinion in that it does
affect the performance of the tests. Immunocompromised
patients include stem cell and solid organ transplant recipi-
ents, patients with autoimmune diseases, patients with
chronic renal failure, HIV-positive patients, and those receiv-
ing immunosuppressive drugs. False-negative results on the
QFT-GIT test for patients with latent and active TB disease
have been reported with a frequency of 4–38% [22]. The grow-
ing list of data existing on the reliability of IGRAs in immuno-
compromised patients show that the prevalence of
indeterminate results may vary depending on the degree of
immunosuppression and the IGRA test used [23]. Table 2
shows a summary of some previous work carried out on the
QFT test and immunocompromised individuals.
Maximilian and Rieger [27] reported that the QFT-GITassay
may be a sensitive tool for the detection and prediction of
active TB in HIV-1 infected individuals based on the small
proportion of indeterminates (47 indeterminates in 830
immunocompromised patients) they got from their study.
An intrinsic problem of this study is that all patients with
active TB disease may not have been identified. Individuals
with a positive QFT-GIT assay result were monitored moreclosely than those with a negative test result. Thus, it is more
likely that patients with TB infection were missed in the
group with negative QFT-GIT assay results. Out of the 739
patients with negative QFT-GIT results, up to 107 had a CD4
count <200. Most of these negatives could have been false
negatives. Many previous studies [25,26,28–31] have con-
firmed the idea that immunocompromised patients with a
CD4 count around or below 200 show false-negative QFT-GIT
results.
The QFT-GIT test depends on the release of IFNc by T-cells
previously sensitized to Mtb-specific antigens (ESAT-6, CFP-
10, TB 7.7). Peripheral blood mononuclear cells are stimulated
in vitro to produce IFN-cwhich is quantified using ELISA. Lym-
phocytopenia causes decreased production of IFN-c and lower
responses to ESAT-6, CFP-10, and TB7.7 antigens [24]. Sec-
ondly, immunosuppressive drugs directly reduce the produc-
tion of inflammatory cytokines such as IFN-c, interleukin-1,
TNF-a, from T-lymphocytes [32–34]. The decrease in IFN-c
induces false negative and indeterminate results due to lower
mitogen, ESAT-6, CFP-10, and TB7.7 antigens levels. Care
should therefore be taken when interpreting negative QFT-
GIT test results in immunocompromised patients because
they may be false-negative results. This is a limit to the use
of the QFT-GIT test in the diagnosis of immunocompromised
patients.
Limit in distinguishing latent from active TB
Exposure to Mtb may result in latent TB infection. A person
with latent TB infection usually lives a healthy life without
developing active TB disease. Two billion people have latent
TB infection but only a fraction (<10 million/y) fall sick with
active TB disease [35]. IGRAs are designed to detect indis-
tinctly both latent and active TB infections. They are ‘‘indirect
tests” because they do not detect the actual TB bacilli but
instead an immune response that suggests past or present
exposure to TB bacilli.
IGRAs, as well as the TST, cannot distinguish between
latent TB infection and active TB disease [31]. In high TB bur-
den communities, with positive QFT-GIT test results in indi-
viduals without any clinical signs of TB, it becomes difficult
to say with certainty whether it is latent TB. In the course
of our work, no report was found on the prediction of values
of the IGRAs to permit the distinction of latent TB from active
TB. A possible approach to this problem would be to find out
further distinguishing antigens if there are any or to associate
various diagnosis tools/methods with QFT-GIT results. Gener-
ally QFT-GIT is interpreted with clinical features or with
results from other direct-detecting assays.
Studies still need to be done to evaluate the concentration
of IFN-c released in latent TB patients in comparison with
those with active TB in order to come up with some predictive
values or cut-off values which might help distinguish latent
from active TB.
Limit in predicting disease progression
QFT-GIT and T-SPOT.TB are not better in predicting disease
progression than the TST in immigrant contact [36].
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The QFT-GIT test is probably not a very accurate diagnostic
technique to be used in monitoring TB treatment. Modifica-
tions in the QFT-GIT test might be of enormous importance
for treatment follow-up like, for example, looking into the
possibility of adding TNF or other distinguishing antigens to
this test or modifying the cut-off values. Care must be taken
when interpreting QFT-test results in immunocompromised
patients, especially in those who are severely immunocom-
promised because a negative test result might not completely
mean absence of TB. Studies oriented towards coming up
with predictive values to distinguish between latent TB infec-
tion and active TB disease or associating it to other diagnostic
tools/methods will help increase the practicality of the QFT
tests.
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